Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Summary

The purpose of this study was to determine if secukinumab is effective and safe in the treatment of plaque type psoriasis

Timeline

Start

2017-02-28

Primary completion

2017-12-21

Completion

2018-11-20

Outcome

Met primary endpoint

registry analysis (superiority test); Secukinumab 150mg vs Placebo; p <0.0001; Odds Ratio (OR) 153.94 (95% CI 54.02 to 438.67); Regression, Logistic NCT03066609 ↗

registry analysis (superiority test); Secukinumab 300mg vs Placebo; p <0.0001; Odds Ratio (OR) 557.98 (95% CI 187.2 to 1663.4); Regression, Logistic NCT03066609 ↗

registry analysis (superiority test); Secukinumab 150mg vs Placebo; p <0.0001; Odds Ratio (OR) 75.82 (95% CI 25.81 to 222.72); Regression, Logistic NCT03066609 ↗

registry analysis (superiority test); Secukinumab 300mg vs Placebo; p <0.0001; Odds Ratio (OR) 149.71 (95% CI 51.83 to 432.42); Regression, Logistic NCT03066609 ↗

Publications

• Cai L, Zhang JZ, Yao X, Gu J, Liu QZ, Zheng M, Zhang SF, Xu JH, Li CX, Cheng H, Guo Q, Pan WL, Li SQ, Li RY, Guo ZP, Song ZQ, Li SS, Dong XQ, Wang L, Fu R, Regnault P, Charef P, Mazur R, Patekar M. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis. Chin Med J (Engl). 2020 Nov 20;133(22):2665-2673. doi: 10.1097/CM9.0000000000001163.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Secukinumab	Monoclonal antibody	150 mg	Subcutaneous
Subject	Secukinumab	Monoclonal antibody	300 mg	Subcutaneous

Indications